Section of Colon and Rectal Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea.
Int J Colorectal Dis. 2013 Dec;28(12):1689-98. doi: 10.1007/s00384-013-1756-z. Epub 2013 Aug 14.
Minimal invasive surgery for mid and low rectal cancer after neoadjuvant long-course chemoradiotherapy (LCRT) can be challenging. The aim of our study was to compare outcomes of laparoscopic and robotic resections in mid and low rectal cancers after LCRT.
Between Jan 2006 and Dec 2010, all patients who underwent robotic or laparoscopic resections for mid and low rectal cancers after LCRT were identified from a prospective database. These patients received treatment (5FU-based chemotherapy, 50.4 Gy radiotherapy), as they were T3 or T4 and/or node + ve. Patients in the two groups were compared with respect to demographics, clinical safety, and oncological outcomes.
One hundred thirty-eight patients underwent rectal cancer resection after LCRT, either robotic (n = 74) or laparoscopic (n = 64). The patients in both groups were comparable in terms of demographics, distance of tumor from anal verge, and type of procedures. There were four (6.3 %) conversions in laparoscopic group and one (1.4 %) in the robotic group (p = 0.183). The morbidity rates in the laparoscopic and robotic group were 26.6 % and 16.2 %, respectively (p = 0.137). With a median follow up of 3 years, the local recurrence in the laparoscopic and robotic group was four (6.3 %) and two (2.7 %), respectively (p = 0.420). The 3-year overall survival rate for laparoscopic and robotic group was 92.1 and 90.0 %, respectively (p = 0.803). The 3-year disease-free survival was also comparable, 78.8 % (laparoscopic) versus 77.7 % (robotic) (p = 0.390).
With a median follow up of 3 years, robotic surgery for mid and low rectal cancer was associated with oncological outcomes comparable to laparoscopic surgery.
新辅助长程放化疗(LCRT)后中低位直肠癌的微创外科治疗具有挑战性。本研究旨在比较 LCRT 后中低位直肠癌腹腔镜和机器人手术的结果。
从前瞻性数据库中确定了 2006 年 1 月至 2010 年 12 月期间所有接受 LCRT 后机器人或腹腔镜中低位直肠癌切除术的患者。这些患者接受了治疗(基于 5FU 的化疗,50.4Gy 放疗),因为他们是 T3 或 T4 和/或淋巴结阳性。比较两组患者的人口统计学、临床安全性和肿瘤学结果。
138 例患者接受了 LCRT 后直肠癌切除术,其中 74 例接受了机器人手术,64 例接受了腹腔镜手术。两组患者在人口统计学、肿瘤距肛门缘的距离和手术类型方面具有可比性。腹腔镜组中有 4 例(6.3%)转为开放手术,而机器人组中有 1 例(1.4%)(p=0.183)。腹腔镜组和机器人组的发病率分别为 26.6%和 16.2%(p=0.137)。中位随访 3 年后,腹腔镜组和机器人组的局部复发率分别为 4 例(6.3%)和 2 例(2.7%)(p=0.420)。腹腔镜组和机器人组的 3 年总生存率分别为 92.1%和 90.0%(p=0.803)。3 年无病生存率也相当,分别为 78.8%(腹腔镜)和 77.7%(机器人)(p=0.390)。
中位随访 3 年后,机器人手术治疗中低位直肠癌的肿瘤学结果与腹腔镜手术相当。